Latest News & Features
Big Pharma
Pharmaceutical company AstraZeneca agreed a deal with ProStrakan Group centring on the rights to the Moventig (naloxegol) drug in Europe. 9 March 2016
Africa
The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications. 9 March 2016
Big Pharma
In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports. 8 March 2016
Biotechnology
The English High Court has allowed Japan-based drug maker Fujifilm Kyowa Kirin Biologics to amend some of its arguments in a patent dispute surrounding AbbVie’s arthritis drug Humira. 8 March 2016
Americas
Pharmaceutical company Teva has bought Mexico-based Representaciones e Investigaciones Médicas, in a deal totalling $2.3 billion. 8 March 2016
Americas
The International Trade Commission has invalidated two patents owned by Jawbone because they cover “ineligible subject matter”, dealing a blow to the wearable fitness company in its legal battle with rival Fitbit. 7 March 2016
Americas
A US court has brought to a close a patent lawsuit that cancer care company Helsinn Healthcare filed against Teva after determining that Helsinn did not trigger the on-sale bar provision when marketing its anti-cancer drug Aloxi (palonosetron). 4 March 2016
Africa
Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains. 3 March 2016
Americas
Amgen and Sandoz are set to go head to head in another patent case, this time centring on Amgen’s arthritis treatment drug Enbrel. 3 March 2016
Asia
Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi. 2 March 2016